Physician profile
John Patrick Sia
NPI 1255597464
$12,055.51
in general payments reported to CMS, 2019-2025
23 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2021: $96.19 · 2022: $433 · 2023: $839 · 2024: $7,642 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,940 · Food and Beverage: $3,141 · Travel and Lodging: $149 · Education: $90.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,940.00 |
| Food and Beverage | $3,141.37 |
| Travel and Lodging | $149.41 |
| Education | $90.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,521.89 | 2024 | Jardiance |
| Lilly USA, LLC | $2,881.54 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $844.25 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $477.29 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $369.37 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $298.43 | 2022-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $274.06 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $203.59 | 2024-2025 | |
| Ardelyx, INC. | $196.14 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $136.01 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $116.57 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Janssen Pharmaceuticals, INC | $91.61 | 2024 | Xarelto |
| Genzyme Corporation | $79.76 | 2023-2025 | |
| Abbvie INC. | $79.19 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $77.10 | 2024 | Inpefa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.27 | 2023-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $68.61 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $63.11 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $53.68 | 2023-2025 | Veltassa |
| Apellis Pharmaceuticals, INC. | $45.30 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $39.80 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.90 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $29.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patrick Sia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.